Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidenc
This study generated real-world evidence on the association of insulin therapy with a higher 5-year HF rate compared to GLP-1 RAs, DPP-4Is, and SGLT2Is based on insurance claims data. These findings also demonstrated the value of real-world data for comparative effectiveness studies to complement established guidelines. On the other hand, the study shares the common limitations of observational studies. Even though high-dimensional confounders are adjusted, remaining confounding may exist and induce bias in the analysis.
Authors
- Jue Hou (ORCID: https://orcid.org/0000-0002-9015-1827)
- Vidul Ayakulangara Panickan
- Anna Plantinga (ORCID: https://orcid.org/0000-0001-6281-7727)
- Clara-Lea Bonzel (ORCID: https://orcid.org/0000-0001-5238-1413)
- Tianxi Cai (ORCID: https://orcid.org/0000-0002-5379-2502)
- SARA JANE CROMER (ORCID: https://orcid.org/0000-0002-4924-2049)
- Rui Duan (ORCID: https://orcid.org/0000-0002-9261-4864)
- Xin Xiong (ORCID: https://orcid.org/0000-0002-1162-5220)
- Xuan Wang (ORCID: https://orcid.org/0000-0002-0011-5663)
Institutions
- University of Minnesota (US)
- Harvard University (US)
- University of Utah (US)
- Williams College (US)
- Massachusetts General Hospital (US)
- Cancer Research And Biostatistics (US)
Publication Details
- Journal
- JMIR Diabetes
- Published
- 2024-09-15
- DOI
- https://doi.org/10.2196/58137
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36